Geron to Webcast KOL Event on June 25, 2019
June 10 2019 - 4:45PM
Geron Corporation (Nasdaq: GERN) today announced that the Company
will webcast an event on June 25, 2019, featuring key opinion
leaders (KOLs) who are authors of imetelstat data presentations
being made at the 24th Annual Congress of the European Hematology
Association (EHA). The KOLs will reprise the presentations made at
EHA, and Geron’s management team will provide an update regarding
progress towards the Company’s 2019 objectives, including the
opening of the planned Phase 3 portion of IMerge for screening and
enrollment in the summer of 2019. The KOL event will begin at 8:00
a.m. ET.
Uwe Platzbecker, M.D., Director, Medical Department I –
Hematology and Cell Therapy, University of Leipzig Medical Center,
Leipzig, Germany, will review efficacy and safety data presented at
EHA from the Phase 2 portion of IMerge, the ongoing Phase 2/3
clinical trial of imetelstat in patients with lower risk
myelodysplastic syndromes.
Rami Komrokji, M.D., Clinical Director, Malignant Hematology
Department Lead Clinical Investigator, Moffitt Cancer Center,
Tampa, Florida, will review analyses presented at EHA of the
overall survival (OS) data from relapsed/refractory myelofibrosis
(MF) patients treated with 9.4 mg/kg of imetelstat in the IMbark
Phase 2 clinical trial, compared to real-world data (RWD) from
closely-matched MF patients who had discontinued treatment from a
JAK inhibitor (JAKi) and were subsequently treated with best
available therapy.
A live audio webcast of the event will be available on Geron’s
website, www.geron.com/investors/events. If you are unable to
listen to the live event, an archived webcast of the event will be
available on the Company’s website for 30 days.
About Imetelstat
Imetelstat is a novel, first-in-class telomerase inhibitor
exclusively owned by Geron and being developed in hematologic
myeloid malignancies. Early clinical data suggest imetelstat may
have disease-modifying activity through the suppression of
malignant progenitor cell clone proliferation, which allows
potential recovery of normal hematopoiesis. Ongoing clinical
studies of imetelstat include a Phase 2/3 trial, called IMerge, in
lower risk myelodysplastic syndromes (MDS) and a Phase 2 trial,
called IMbark, in Intermediate-2 to High-risk myelofibrosis.
Imetelstat received Fast Track designation from the United States
Food and Drug Administration for the treatment of patients with
transfusion-dependent anemia due to lower risk MDS who are
non-del(5q) and refractory or resistant to an erythroid stimulating
agent.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in hematologic
myeloid malignancies. For more information about Geron, visit
www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this
press release contains forward-looking statements made pursuant to
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such statements,
include, without limitation, those regarding: (i) that the Phase 3
portion of IMerge is planned to open for screening and enrollment
in the summer of 2019; (ii) that imetelstat may have
disease-modifying activity; and (iii) other statements that are not
historical facts, constitute forward-looking statements. These
statements involve risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking
statements. These risks and uncertainties, include, without
limitation, risks and uncertainties related to: (i) whether the
Company overcomes all the clinical, safety and efficacy,
operational, technical, scientific, manufacturing and regulatory
challenges to enable the opening of the planned Phase 3 portion of
IMerge for screening and enrollment in the summer of 2019; (ii)
whether regulatory authorities permit the further development of
imetelstat on a timely basis, or at all, without any clinical
holds; and (ii) whether imetelstat demonstrates disease-modifying
activity. Additional information on the above risks and
uncertainties and additional risks, uncertainties and factors that
could cause actual results to differ materially from those in the
forward-looking statements are contained in Geron’s periodic
reports filed with the Securities and Exchange Commission under the
heading “Risk Factors,” including Geron’s quarterly report on Form
10-Q for the quarter ended March 31, 2019. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made, and the facts and assumptions underlying
the forward-looking statements may change. Except as required by
law, Geron disclaims any obligation to update these forward-looking
statements to reflect future information, events or
circumstances.
CONTACT:
Suzanne MessereInvestor and Media
Relationsinvestor@geron.commedia@geron.com
CG Capital877-889-1972
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2024 to May 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From May 2023 to May 2024